The in vitro biological activity towards the MDA-MB-231 triple-negative breast cancer cell line of two different series of anionic Pt(II) organometallic complexes was tested. For the first time, cytotoxic activity of anionic Pt(II) complexes has been observed. The anionic compounds of general formula NBu4[(C^N)Pt(O^O)], where (C^N) represents the cyclometalated form of 2-phenylpyridine (H(PhPy)), 2-thienylpyridine (H(Thpy)) or 2-benzo[h]quinoline (H(Bzq)), feature two different (O^O) chelated ligands: tetrabromocatechol [BrCat]2− (1–3) or alizarine [Aliz]2− (4–6). Complexes 1–6 displayed a significant cytotoxic effect against the studied cell line (IC50 range of 1.9–52.8 μM). For BrCat-containing complexes 1–3, the biological activity was independent of the nature of the coordinated (C^N) ligand. In contrast, in the case of 4–6, the cytotoxicity (significantly high for 4) was concomitantly induced by the presence of either the PhPy or the [Aliz]2− ligand. Since complexes 1–6 are emissive in solution, the potential use of 4 as a theranostic agent was investigated using confocal analysis. The fluorescence signal from MDA-MB-231 cells incubated with 4 indicated the localization of the compound into the cytosol region.
Cytotoxic performances of new anionic cyclometalated Pt(II) complexes bearing chelated O^O ligands / A. Ionescu, R. Caligiuri, N. Godbert, L. Ricciardi, M. La Deda, M. Ghedini, N. Ferri, M.G. Lupo, G. Facchetti, I. Rimoldi, I. Aiello. - In: APPLIED ORGANOMETALLIC CHEMISTRY. - ISSN 0268-2605. - 34:3(2020 Jan).
|Titolo:||Cytotoxic performances of new anionic cyclometalated Pt(II) complexes bearing chelated O^O ligands|
RIMOLDI, ISABELLA (Penultimo)
|Parole Chiave:||anionic Pt(II) complexes; cytotoxicity; MDA-MB-231 cell line; O^O ligands|
|Settore Scientifico Disciplinare:||Settore CHIM/03 - Chimica Generale e Inorganica|
Settore BIO/14 - Farmacologia
|Data di pubblicazione:||gen-2020|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1002/aoc.5455|
|Appare nelle tipologie:||01 - Articolo su periodico|